Cargando…

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15

CD1d-restricted invariant natural killer T cells (iNKT cells) may play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Interleukin (IL)-15 is a pro-inflammatory cytokine which is over-expressed in SLE patients. In the present study, we investigated the iNKT cell expansio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chien-Ya, Chueh, Yu-Shan, Kuo, Ming-Ling, Lee, Pei-Tzu, Hsiao, Hsiu-Shan, Huang, Jing-Long, Lin, Syh-Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694473/ https://www.ncbi.nlm.nih.gov/pubmed/34936686 http://dx.doi.org/10.1371/journal.pone.0261727

Ejemplares similares

Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus
por: Lin, Syh-Jae, et al.
Publicado: (2016)

Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2017)

Cytotoxic Function and Cytokine Production of Natural Killer Cells and Natural Killer T-Like Cells in Systemic Lupus Erythematosis Regulation with Interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2019)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2020)

Modulatory Function of Invariant Natural Killer T Cells in Systemic Lupus Erythematosus
por: Chuang, Yi-Ping, et al.
Publicado: (2012)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
por: Uchida, Takahiro, et al.
Publicado: (2018)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines
por: Davitt, Christopher J. H., et al.
Publicado: (2019)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
por: Singh, Shailbala, et al.
Publicado: (2014)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis
por: Becker-Merok, Andrea, et al.
Publicado: (2006)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity
por: Lieberman, Linda A., et al.
Publicado: (2010)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus
por: Yen, Chung-Yang, et al.
Publicado: (2022)

15. Uncommon CNS manifestation in systemic lupus erythematosus
por: Zun Swe, May, et al.
Publicado: (2018)

Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis
por: Teixeira, Vítor, et al.
Publicado: (2018)

Toll-like Receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes
por: Ando, Tatsuya, et al.
Publicado: (2013)

The role of tumor necrosis factor-alpha in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2008)

Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness
por: Segerberg, Filip, et al.
Publicado: (2019)

An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses
por: Longet, Stephanie, et al.
Publicado: (2019)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

Treatment of Bullous Systemic Lupus Erythematosus
por: Duan, Lihua, et al.
Publicado: (2015)

IL-17 in Systemic Lupus Erythematosus
por: Crispín, José C., et al.
Publicado: (2010)

Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells
por: Manco, Roberta, et al.
Publicado: (2023)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice
por: Khan, Arshad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_40ou6bcvv6c7pbafi4ured4oas